Heagney v. John Paul Mitchell Systems

District Court, N.D. California·Decided August 2, 2023·No. 3:23-cv-00687·Unknown

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

RANDALL HEAGNEY, et al., Case No. 23-cv-00687-VC

Plaintiffs, ORDER DENYING IN PART AND v. GRANTING IN PART MOTION TO DISMISS JOHN PAUL MITCHELL SYSTEMS, Re: Dkt. Nos. 32, 33 Defendant.

The motion to dismiss is denied in part and granted in part. The consumers plausibly state false advertising and breach of warranty claims, and it is not obvious from the pleadings that those claims are barred by the statute of limitations. But the consumers lack standing for injunctive relief. This ruling assumes the reader is familiar with the facts, the applicable legal standard, and the arguments made by the parties. False advertising. The consumers have done enough to state a false advertising claim. As the complaint tells it, Paul Mitchell has long marketed its business and its products as “cruelty- free.” See Dkt. No. 28 ¶¶ 48–73. The plaintiffs say they took Paul Mitchell at its word and bought some of those products. But Paul Mitchell, they allege, once imported those products into China and registered them with the Chinese government—at a time when Chinese law required that companies test cosmetic imports on animals as a condition of registration. See Dkt. No. 28 ¶¶ 118–30, 136, 143–56. And, according to the complaint, Paul Mitchell was not exempt from that requirement. See Dkt. No. 28 ¶¶ 195, 200, 212. Read together and taken as true, these allegations plausibly suggest that Paul Mitchell tested some of its cosmetic products on animals and that its contrary “cruelty-free” advertising misled reasonable consumers. Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 557 (2007); see Williams v. Gerber Products Co., 552 F.3d 934, 938 (9th Cir. 2008). Paul Mitchell insists that there’s another explanation for all of this. Maybe the company did have an exemption. Maybe China wasn’t enforcing its import registration laws. Or maybe something was “lost in translation” when the consumers reached out to the Chinese government to inquire whether Paul Mitchell was exempt. Each of these explanations might be possible, but none are so “natural” or “obvious” as to make the complaint implausible. Twombly, 550 U.S. at 567–68; see also Starr v. Baca, 652 F.3d 1202, 1216 (9th Cir. 2011). Paul Mitchell is also wrong to argue that the complaint presents a “lack of substantiation” challenge. The consumers have not merely alleged that the “cruelty-free” labels are false and left it at that, thereby “forcing the defendant to produce evidence that the claim is true.” National Council Against Health Fraud v. King Bio Pharmaceuticals, Inc., 107 Cal. App. 4th 1336, 1345 (2003). Instead, the complaint offers specific allegations—the import registry, the relevant Chinese regulations, and confirmation from the appropriate Chinese agency—“pointing to actual falsehood.” Kwan v. SanMedica International, 854 F.3d 1088, 1096 (9th Cir. 2017). It’s true that more direct evidence “establishing falsity”—like “specific test reports, knowledgeable persons, or third-party articles”—would strengthen the consumers’ case. ECF No. 32, at 8 (Motion to Dismiss). “But at the motion to dismiss stage, complaints need not ‘show’ or ‘establish’ anything.” Locklin v. StriVectin Operating Company, Inc., 2022 WL 867248, at *4 (N.D. Cal. Mar. 23, 2022) (citing Ashcroft v. Iqbal, 446 U.S. 662, 678 (2009)). The standard is plausibility, and the complaint here satisfies it.1

Free access — add to your briefcase to read the full text and ask questions with AI

Heagney v. John Paul Mitchell Systems, (N.D. Cal. 2023).

Heagney v. John Paul Mitchell Systems (Heagney v. John Paul Mitchell Systems) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Williams v. Gerber Products Co.
552 F.3d 934 (Ninth Circuit, 2008)
National Council Against Health Fraud, Inc. v. King Bio Pharmaceuticals, Inc.
133 Cal. Rptr. 2d 207 (California Court of Appeal, 2003)
Fox v. Ethicon Endo-Surgery, Inc.
110 P.3d 914 (California Supreme Court, 2005)
Kwan v. SanMedica International
854 F.3d 1088 (Ninth Circuit, 2017)
Karim Khoja v. Orexigen Therapeutics, Inc.
899 F.3d 988 (Ninth Circuit, 2018)
Starr v. Baca
652 F.3d 1202 (Ninth Circuit, 2011)
Ries v. Arizona Beverages USA LLC
287 F.R.D. 523 (N.D. California, 2012)
Davidson v. Kimberly-Clark Corp.
889 F.3d 956 (Ninth Circuit, 2017)